Beckley Psytech and Atai Life Sciences have reported promising results from mid-stage clinical trials of psychedelic-based treatments targeting treatment-resistant depression. Beckley's intranasal BPL-003 formulation demonstrated significant symptom reductions compared to control in a Phase 2b study, achieving primary and secondary endpoints. The progress catalyzed a merger between Beckley and Atai, positioning the combined entity to advance regulatory filings amid a shifting psychiatric drug landscape increasingly embracing psychedelic modalities.